NCT06814106View on ClinicalTrials.gov

A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

May 8, 2023

Study Completion Date

May 8, 2023

Conditions
Healthy
Interventions
DRUG

Enlicitide Chloride

Oral Capsule

DRUG

Placebo

Placebo oral capsule matching enlicitide chloride

Trial Locations (1)

200032

Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001), Shanghai

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY